Biotechnology and drug discovery platform company
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about OmniAb, Inc..
The 2 sources with the most insights about OmniAb, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Appeared in the performance-screen review without a specific investment thesis.
Strong bullish stance driven by royalty upside on a Johnson & Johnson drug candidate that could potentially become one of the biggest drugs globally.
Appeared in the performance-screen review without a specific investment thesis.
Strong bullish stance driven by royalty upside on a Johnson & Johnson drug candidate that could potentially become one of the biggest drugs globally.
Other assets that creators frequently mention in the same content as OmniAb, Inc..
The most active sources covering OmniAb, Inc. (OABI) on Kazuha are @realmartinshkreli, @shkreliplanet. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about OmniAb, Inc. (OABI) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering OmniAb, Inc. (OABI) most frequently also discuss SLS, WDC, AMD, SBUX, TXG. See the "Discussed alongside" section above for full asset pages.